Investigation to Efficacy and Safety of CC-90001 in patients with Idiopathic Pulmonary Fibrosis : A Phase 2, 24-Week Randomized, Double-blind, Placebo-ControlledMulticenter Study, With an 80-Week Active Treatment Extension, toEvaluate the Efficacy and Safety of CC-90001 in Subjects with IdiopathicPulmonary Fibrosis

Medienart:

Klinische Studie

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

WHO International Clinical Trials Registry Platform - (2023) vom: 21. Juni Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
Medical Condition: IDIOPATHIC PULMONARY FIBROSIS MedDRA version: 20.0Level: LLTClassification code 10067761Term: Exacerbation of idiopathic pulmonary fibrosisSystem Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Phase: Phase 2
Recruitment Status: Authorised-recruitment may be ongoing or finished
Study Type: Interventional

Anmerkungen:

WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 24-02-2017, Last updated: 2023-06-29

ICTRP ID:

EUCTR2016-003473-17-GB
CC-90001-IPF-001

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

CTG004733541